Guselkumab for the treatment of moderate-to-severe plaque psoriasis

Expert Review of Clinical Pharmacology
Eric J YangTina Bhutani

Abstract

Guselkumab is a human monoclonal antibody targeting the p19 subunit of IL-23 that has been approved for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This medication blocks the IL-23/IL-17 axis, which has been implicated in playing a key role in the pathogenesis of psoriasis. Areas covered: This review outlines the pharmacologic properties, safety, and efficacy of guselkumab for the treatment of plaque psoriasis. Expert commentary: Guselkumab is the first IL-23 specific inhibitor to be approved for the treatment of plaque psoriasis. Phase II and III clinical trial results have demonstrated excellent safety and efficacy of guselkumab. IL-23 inhibitors may offer potential benefits over existing therapies for moderate-to-severe plaque psoriasis in terms of safety, frequency of administration, and efficacy. Long-term safety data will be critical in evaluating the role of guselkumab in the treatment of psoriasis.

References

Jan 1, 1983·Archives of Dermatological Research·J D BosR H Cormane
Nov 1, 1995·The Journal of Experimental Medicine·M F NeurathW Strober
Mar 1, 1993·International Journal of Dermatology·M A GuptaC N Ellis
Dec 1, 1996·European Journal of Immunology·K W McIntyreJ Magram
Aug 25, 1999·Journal of the American Academy of Dermatology·S R RappD M Reboussin
Nov 6, 2002·The Journal of Biological Chemistry·Sudeepta AggarwalAustin L Gurney
Jul 9, 2004·The Journal of Experimental Medicine·Estelle BettelliVijay K Kuchroo
May 4, 2006·The Journal of Clinical Investigation·Yoichiro Iwakura, Harumichi Ishigame
Dec 19, 2007·Archives of Dermatology·Joel M GelfandBrian L Strom
Jul 31, 2009·The New England Journal of Medicine·Frank O NestleJonathan Barker
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Nov 29, 2013·The Journal of Investigative Dermatology·Emmilia A DowlatshahiTamar Nijsten
Jan 7, 2014·Journal of the American Academy of Dermatology·Tara D RachakondaApril W Armstrong
Apr 1, 2014·The Journal of Allergy and Clinical Immunology·Howard SofenJames G Krueger
Jul 15, 2015·The New England Journal of Medicine·Kenneth B GordonKristian Reich
Jul 19, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Heather R Conti, Sarah L Gaffen
Oct 1, 2015·The New England Journal of Medicine·Mark LebwohlAjay Nirula
Jun 15, 2016·The New England Journal of Medicine·Kenneth B GordonUNKNOWN UNCOVER-3 Study Group
Apr 20, 2017·The New England Journal of Medicine·Kim A PappSteven J Padula
Oct 8, 2017·Journal of the American Academy of Dermatology·Mark G LebwohlRobert J Israel

❮ Previous
Next ❯

Citations

Apr 1, 2020·Dermatologic Therapy·L Rodriguez Fernandez-FreireR Ruiz-Villaverde
Jun 2, 2020·Experimental Dermatology·Carmen de Jesús-GilLuis F Santamaria-Babí

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved